RAB0540
Human FGF19 / Fibroblast Growth Factor 19 ELISA Kit
for serum, plasma, cell culture supernatants and urine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41116158
NACRES:
NA.32
Recommended Products
species reactivity
human
packaging
kit of 96 wells (12 strips x 8 wells)
technique(s)
ELISA: suitable
input
sample type urine
sample type plasma
sample type cell culture supernatant(s)
sample type serum
assay range
inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 30 pg/mL
detection method
colorimetric
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... FGF19(9965)
General description
This ELISA antibody pair detects human Fibroblast Growth Factor 19.
Application
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Biochem/physiol Actions
Fibroblast growth factor (FGF) 19 controls bile acid, fatty acid, glucose and phosphate metabolism in target organs by activating FGF receptor 4. FGF19 regulates hepatic protein and glycogen metabolism via activation of insulin-independent endocrine pathway. In diabetic mice, FGF19 reduces the levels of serum glucose and triglycerides. Overexpression of the gene leads to the development of hepatocellular carcinoma (HCC).
Other Notes
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
Kit Components Also Available Separately
Product No.
Description
SDS
signalword
Warning
hcodes
pcodes
Hazard Classifications
Met. Corr. 1
Storage Class
8A - Combustible corrosive hazardous materials
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
H Johansson et al.
Journal of internal medicine, 287(5), 534-545 (2020-01-25)
Fibroblast growth factor 19 (FGF19) is produced in the small intestine and is involved in suppression of hepatic bile acid (BA) synthesis. FGF19 is also expressed in the liver and serum levels are elevated in adults with cholestatic liver disease.
Kai Wang et al.
Cell reports, 26(1), 222-235 (2019-01-04)
We demonstrated the metabolic benefits of Parabacteroides distasonis (PD) on decreasing weight gain, hyperglycemia, and hepatic steatosis in ob/ob and high-fat diet (HFD)-fed mice. Treatment with live P. distasonis (LPD) dramatically altered the bile acid profile with elevated lithocholic acid (LCA)
José O Alemán et al.
Journal of translational medicine, 16(1), 244-244 (2018-09-05)
Microbiota and bile acids in the gastrointestinal tract profoundly alter systemic metabolic processes. In obese subjects, gradual weight loss ameliorates adipose tissue inflammation and related systemic changes. We assessed how rapid weight loss due to a very low calorie diet
Samer Al-Dury et al.
Journal of hepatology, 71(5), 986-991 (2019-06-30)
The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. We aimed to determine whether OCA treatment increases the risk of gallstone formation. Twenty patients awaiting laparoscopic cholecystectomy were randomized to
Meilin Wei et al.
EBioMedicine, 55, 102766-102766 (2020-05-15)
The composition of the bile acid (BA) pool is closely associated with obesity and is modified by gut microbiota. Perturbations of gut microbiota shape the BA composition, which, in turn, may alter important BA signaling and affect host metabolism. We
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service